Welcome to our dedicated page for IGC Pharma SEC filings (Ticker: IGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IGC Pharma, Inc. (NYSE American: IGC) SEC filings page on Stock Titan aggregates the company’s official disclosures to the U.S. Securities and Exchange Commission, providing a structured view of its regulatory and corporate history. As a Maryland-incorporated, clinical-stage biotechnology company focused on Alzheimer's disease, pharmaceutical cannabinoids, and AI-driven research, IGC Pharma uses SEC filings to report material events, capital transactions, governance actions, and financial reporting changes.
Investors reviewing IGC Pharma’s filings will find multiple Form 8-K current reports detailing key developments. Recent 8-Ks describe a registered direct offering under an effective Form S-3 shelf registration statement, including a Subscription Agreement for the sale of common stock and the intended use of proceeds for working capital and clinical development programs. Other 8-Ks outline the completion of a Sale of Assets and Manufacturing Agreement through the company’s Holi Hemp LLC subsidiary, documenting the disposition of certain equipment, inventory, and operating assets of a Vancouver, Washington facility and the associated preferential supply rights and contingent consideration.
Additional 8-K filings and the DEF 14A proxy statement provide information on corporate governance and capital structure. These documents cover stockholder approval to increase authorized common stock from 150,000,000 to 600,000,000 shares, amendments to the Articles of Incorporation to implement that increase, and the election of directors and ratification of the independent registered public accounting firm. Another 8-K reports a change in fiscal year-end from March 31 to December 31 and the plan to file a transition report on Form 10-K for the nine-month period from April 1, 2025, through December 31, 2025.
Through Stock Titan, users can access IGC Pharma’s 10-K, 10-Q, 8-K, and proxy materials as they appear on EDGAR, along with AI-powered summaries that highlight the main points of lengthy documents. These summaries help explain complex topics such as equity offerings under a shelf registration, asset sale terms, changes in authorized share capital, or fiscal year transitions. The filings page is also the place to monitor exhibits such as material contracts, legal opinions, and pro forma financial information referenced in 8-Ks.
For those tracking IGC Pharma’s stock, this page offers a way to review how the company reports on its clinical-stage operations, capital planning, governance decisions, and other material events through official SEC channels, with AI tools available to make dense regulatory text more accessible.
IGC Pharma director Richard K. Prins exercised restricted stock units into common shares of the company. On April 1, 2026, he converted 170,000 restricted stock units into 170,000 shares of common stock at an exercise price of $0.00 per share. Following these transactions, he directly holds 1,541,251 shares of IGC Pharma common stock. The units were granted in June 2023 and March 2024 and vest in equal installments over three years, with each unit representing one share of common stock.
IGC Pharma, Inc. CEO Mukunda Ram reported multiple equity award exercises on April 1, 2026. He exercised restricted stock units and stock options to acquire a total of 706,409 shares of common stock, including shares held indirectly through his spouse, with no open-market sales.
Following these transactions, Ram directly holds 4,649,088 shares of IGC Pharma common stock, while his spouse holds an additional 910,751 shares reported as indirect ownership. The filing reflects routine compensation-related vesting and option exercises rather than discretionary buying or selling.
IGC Pharma director James P. Moran reported routine equity compensation activity involving restricted stock units (RSUs). On April 1, 2026, he exercised 80,000 RSUs and 50,000 RSUs, each RSU converting into one share of IGC common stock at a $0.00 exercise price. These RSUs stem from grants made on June 20, 2023 and March 13, 2024 that vest in equal annual installments over three years. Following the conversions, Moran directly owns 1,235,735 shares of IGC Pharma common stock, with no open‑market sales disclosed in this filing.
IGC Pharma director and PFO Claudia Grimaldi exercised equity awards to acquire additional common stock. On April 1, 2026, she converted 100,000 Restricted Stock Units into 100,000 shares of common stock and exercised options for 138,462 shares at an exercise price of $0.26 per share.
These exercises increased her direct holdings to 1,372,714 shares of common stock. The RSUs and options were originally granted in June 2023 and March 2024, respectively, and vest in equal installments over three years.
IGC Pharma, Inc. entered into a strategic 12-part national media partnership with FMW Media Works’ New to The Street platform to support its investor relations and corporate communications. The campaign will use long-form TV interviews, commercials, digital channels, and outdoor placements in major U.S. financial markets.
IGC will appear on sponsored programming on Fox Business and Bloomberg Television, with additional reach through more than 4.45 million YouTube subscribers, Times Square and New York City Financial District billboards, and curated events aimed at accredited investors. The company frames this effort as enhancing investor awareness while it advances its clinical-stage Alzheimer’s and metabolic disorder pipeline.
IGC Pharma, Inc. filed a Transition Report on Form 10-KT for the nine-month fiscal transition period ended December 31, 2025 following a Board-approved change of fiscal year end from March 31 to December 31. The company remains a clinical-stage biotech focused on Alzheimer’s disease; its lead candidate, IGC-AD1, is in a Phase 2 CALMA trial for agitation in Alzheimer’s dementia with approximately two-thirds of target enrollment completed and interim signals reported from an initial n=26 cohort showing reductions in agitation and exploratory sleep improvements. Nonclinical work during the period included a genetic toxicology study that did not identify genotoxic risk. Financially, cash and cash equivalents were approximately $900,000 and the company reported a working capital deficit of approximately $366,000 as of December 31, 2025. Shares outstanding were 98,796,089 as of March 11, 2026.
IGC Pharma, Inc. entered into new financing arrangements, including a promissory note with Vanquish Funding Group Inc. for a total principal of $353,050, reflecting an original issue discount of $46,050 on a cash purchase price of $307,000. The note matures on February 28, 2027 and can be prepaid at any time with notice. If an event of default occurs and continues, Vanquish may convert the outstanding balance into common shares at 75% of the lowest trading price over the prior 10 trading days, subject to a 4.99% beneficial ownership cap and a 19.99% conversion cap absent shareholder approval. IGC also obtained approximately $219,000 in additional financing through a loan agreement with One Deck Capital, Inc. Both financings are intended for general working capital and other corporate purposes.
IGC Pharma's CEO and director Ram Mukunda reported indirect transactions involving his spouse's holdings. On February 3, 2026, his spouse acquired 50,000 shares of common stock at $0.0 per share, bringing indirectly held common stock to 860,752 shares.
On the same date, the spouse was granted 16,667 restricted stock units that vest immediately and 66,666 restricted stock units that vest over time, both indirectly attributed "BY SPOUSE." Each restricted stock unit represents the right to receive one share of IGC common stock.
IGC Pharma director reports RSU conversion into common stock. On January 19, 2026, director Richard K. Prins exercised 100,000 restricted stock units, which were granted on March 13, 2024 and vest when specific board-approved milestones are achieved. Each unit represents the right to receive one share of IGC common stock, and the transaction was reported at an exercise price of $0.0 per unit. Following this transaction, Prins directly holds 1,371,251 shares of common stock and 50,000 restricted stock units.
IGC Pharma, Inc. entered into a Subscription Agreement for a registered direct offering of 779,997 shares of common stock at $0.30 per share, for gross proceeds of approximately $234 thousand before expenses. The offering is being made under an effective Form S-3 shelf registration statement and a related prospectus supplement dated January 5, 2026. Closing is expected to occur on or about January 5, 2026, subject to customary closing conditions. IGC plans to use the net proceeds for working capital and general corporate purposes, including funding clinical development programs, research and development activities, and other business initiatives.